Arcus Biosciences Appoints David Beier to Its Board of Directors
December 18, 2017 05:00 AM Eastern Standard Time HAYWARD, Calif.–Arcus Biosciences, a clinical stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of David Beier, J.D….Read More
Arcus Biosciences Announces $107 Million Series C Financing Led by GV and Initiation of Two Clinical Trials
November 13, 2017 07:30 AM Eastern Standard Time HAYWARD, Calif. Arcus Biosciences, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today the completion…Read More
Arcus Biosciences Announces Option and License Agreement with Taiho Pharmaceutical Co. Ltd.
September 19, 2017 09:30 PM Eastern Daylight Time HAYWARD, Calif. Arcus Biosciences, a US-based biotechnology company focused on the discovery and development of innovative cancer immunotherapies, announced today that it…Read More
AB928 is a potent and selective dual antagonist of the adenosine receptors known as A2aR and A2bR.
AB154 is a monoclonal antibody (mAb) that potently and selectively blocks a novel immune checkpoint called TIGIT.
AB122 is a monoclonal antibody (mAb) that potently and selectively blocks a protein called PD-1.
AB680 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine.